\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space AI ContinentThe European Commission has launched a consultation on a Code of Practice fo proivdes of general-purpose Artificial Intelligence (GPAI) models.
The Commission invites GPAI providers with operations in the EU, businesses, civil society representatives, rights holders and academic experts to submit their views and findings, which will feed into the Commission's upcoming draft of the Code of Practice on GPAI models. Interested parties are also invited to provide input on ensuring trustworthy general-purpose AI models in the EU.
The Code of Practice, foreseen by the Artificial Intelligence Act (AI Act), will address critical areas such as transparency, copyright-related rules, risk identification and assessment, risk mitigation, and internal risk management.
In addition, the feedback from the consultation will also inform the work of the AI Office, which will supervise the implementation and enforcement of the AI Act rules on GPAI. The AI Office is developing a template and guidelines for summarising training data, used to build the GPAI model. The template and guidelines will be adopted by the Commission and contribute to further discussions on the Code.
The AI Act, which enters into force on 1 August 2024, aims to foster responsible AI development and deployment in the EU. The provisions on GPAI will enter into application 12 months after the AI Act enters into force. The Commission expects to finalise the Code of Practice by April 2025.
Participants can find more information on the consultation on the Code of Practice for GPAI (deadline to submit your views 10 September), as well as information on how to join the upcoming drafting process (deadline for expression of interest 25 August).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
